Avadel Pharmaceuticals (AVDL) Accumulated Expenses (2016 - 2022)
Historic Accumulated Expenses for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $8.0 million.
- Avadel Pharmaceuticals' Accumulated Expenses fell 884.64% to $8.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was $8.0 million, marking a year-over-year decrease of 884.64%. This contributed to the annual value of $7.2 million for FY2021, which is 999.85% up from last year.
- Latest data reveals that Avadel Pharmaceuticals reported Accumulated Expenses of $8.0 million as of Q3 2022, which was down 884.64% from $9.7 million recorded in Q2 2022.
- Over the past 5 years, Avadel Pharmaceuticals' Accumulated Expenses peaked at $45.9 million during Q1 2018, and registered a low of $4.3 million during Q1 2021.
- Its 5-year average for Accumulated Expenses is $15.0 million, with a median of $14.9 million in 2020.
- In the last 5 years, Avadel Pharmaceuticals' Accumulated Expenses soared by 13047.75% in 2018 and then plummeted by 7107.96% in 2021.
- Quarter analysis of 5 years shows Avadel Pharmaceuticals' Accumulated Expenses stood at $21.7 million in 2018, then dropped by 8.69% to $19.8 million in 2019, then tumbled by 67.18% to $6.5 million in 2020, then increased by 10.0% to $7.2 million in 2021, then increased by 11.38% to $8.0 million in 2022.
- Its Accumulated Expenses stands at $8.0 million for Q3 2022, versus $9.7 million for Q2 2022 and $9.4 million for Q1 2022.